Wells Fargo & Company Vectiv Bio Holding Ag Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	BUY	$7.79 - $8.98 $32,640 - $37,626	4,190 New	4,190 $36,000
Q2 2022 Aug 12, 2022	SELL	$4.2 - $6.55 $4,620 - $7,205	-1,100 Reduced 85.34%	189 $1,000
Q1 2022 May 16, 2022	SELL	$4.6 - $5.8 $7,428 - $9,367	-1,615 Reduced 55.61%	1,289 $6,000
Q4 2021 Feb 14, 2022	SELL	$2.83 - $7.26 $2,830 - $7,260	-1,000 Reduced 25.61%	2,904 $14,000
Q3 2021 Nov 15, 2021	BUY	$6.7 - $11.54 $1,393 - $2,400	208 Added 5.63%	3,904 $30,000
Q2 2021 Aug 16, 2021	BUY	$11.66 - $24.23 $43,095 - $89,554	3,696 New	3,696 $43,000

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.